ASKB589 + capecitabine + oxaliplatin + tislelizumab

This is an **investigational combination therapy** consisting of ASKB589 (a recombinant, second-generation humanized monoclonal antibody targeting Claudin 18.2, with ADCC enhancement), capecitabine (a small molecule oral prodrug of 5-fluorouracil), oxaliplatin (a platinum-based chemotherapeutic agent), and tislelizumab (a monoclonal antibody PD-1 immune checkpoint inhibitor). It is being evaluated as a first-line treatment for advanced, recurrent, or metastatic **gastric cancer** and **gastroesophageal junction cancer** positive for CLDN18.2 expression[1][3][5]. The regimen leverages **targeted therapy** (ASKB589), **immunotherapy** (tislelizumab), and **chemotherapy** (CAPOX: capecitabine + oxaliplatin) to induce tumor cell death via multiple mechanisms: direct cytotoxicity, enhanced immune response, and ADCC/CDC[1][3][5].

Brand names

no unique brand name for this combination

Other names

CAPOX + ASKB589 + tislelizumabanti-claudin18.2 antibody (ASKB589) + capecitabine + oxaliplatin + PD-1 inhibitor (tislelizumab)